Connect with us


COVID-19 vaccination opportunities: week of April 4, 2022 – Public Health Sudbury & Districts



Public Health Sudbury & Districts is offering several convenient opportunities in the Sudbury & Manitoulin districts this week to help you get your COVID-19 vaccine. Don’t delay. Get your first and second dose as soon as possible and your third dose if you are eligible.

Vaccination opportunities for the week of April 4

More opportunities may be added throughout the week. For regular updates, follow us on social media @PublicHealthSD (Facebook, Twitter). Visit us online for up-to-date clinic details, including the clinic times and mRNA vaccine brand that is planned at

Tuesday, April 5

Appointment and walk-in clinics

  • Carmichael Arena, Greater Sudbury
  • Freshwater Community Church, Mindemoya, Manitoulin Island
  • Foodland, Noëlville (mobile bus clinic)

Wednesday, April 6

Appointment and walk-in clinics

  • Charles C. McLean Public School, Gore Bay, Manitoulin Island
  • Southridge Mall, Greater Sudbury

Walk-in clinics

  • St. Stanislas Church, Copper Cliff (mobile bus clinic)

Thursday, April 7

Appointment and walk-in clinics

  • Carmichael Arena, Greater Sudbury
  • Lansdowne Public School, Greater Sudbury
  • S. Geiger Public School, Massey

Walk-in clinics

  • Ryan Heights Playground, Greater Sudbury (mobile bus clinic)

Friday, April 8

Appointment and walk-in clinics

  • Dowling Leisure Centre, 79 Main Street West, Dowling
  • Falconbridge Community Centre, Falconbridge (mobile bus clinic)
  • Southridge Mall, Greater Sudbury

Saturday, April 9

Appointment and walk-in clinics

  • Dr. Edgar Leclair Community Centre and Arena, Azilda

Walk-in clinics

  • 1099 Marcus Drive, Greater Sudbury (mobile bus clinic)

Sensory-friendly service

Sensory-friendly is a service for individuals who require accommodations for sensory sensitivities during immunization.

How it works: Sensory-friendly services may include a private immunization station at one of our mass clinics where lights can be dimmed, noise kept to a minimum, and extra time allotted for the appointment. Alternatively, vaccine-to-vehicle service can be provided within a vehicle at the parking lot of a mass clinic as an alternative for those requiring sensory accommodations.

How to book: Appointments can only be booked by phone through the local call centre at 705.674.2299 (toll-free: 1.800.708.2505). The call centre is open Monday to Friday between 8 a.m. and 6 p.m. and is closed on statutory holidays.  Booking online is not available.

Vaccine-to-vehicle service

Vaccine-to-vehicle is a service available at select mass immunization clinics. This service is available for individuals who are unable to receive their vaccine within a clinic setting for reasons such as sensory sensitivities, decreased mobility, or other health concerns.

How it works: An immunizer will come outside to the parking lot to provide the vaccine to individuals in their vehicle.

How to book: Appointments can only be booked by phone through the local call centre at 705.674.2299 (toll-free: 1.800.708.2505). The call centre is open Monday to Friday between 8 a.m. and 6 p.m. and is closed on statutory holidays.  Booking online is not available.

Please note that during extreme weather or extreme cold that your appointment may be rebooked to ensure everyone’s safety.

Pharmacies and primary care

With many pharmacies and primary care providers providing COVID-19 vaccination, there are even more options available to get your first or second dose locally, every week. Visit (Government of Ontario) for a list of pharmacies in Ontario offering COVID-19 vaccination and for booking information or contact your primary care provider.

Questions about vaccination

Whether you have questions about getting your first, second, or third dose of vaccine or you have questions about youth vaccination, our clinic immunizers as well as our call centre staff can help answer your questions. Your health care provider is also a trusted source of reliable and credible information. Choosing vaccination is a choice and everyone deserves to have the information they need to be well informed.

Vaccine brands offered and supplies

All Public Health clinics offer one of two mRNA vaccine brands—either Moderna Spikevax or the pediatric and adult dose of Pfizer-BioNTech Comirnaty. A reminder that for those 30 and older, the adult dose of Pfizer-BioNTech Comirnaty and Moderna Spikevax vaccines can be safely interchanged. Based on vaccine supplies, the vaccine brand planned for use at any clinic is subject to change, possibly with limited notice. We encourage you to ask our immunizers for more information to help you make an informed decision and feel comfortable about getting either vaccine brand. To learn which mRNA vaccine brands are planned for our clinics, visit

Currently, mRNA COVID-19 vaccines (Pfizer-BioNTech Comirnaty or Moderna Spikevax) are the preferred COVID-19 vaccine options for the primary series and booster doses administered at all Public Health clinics. However, Public Health also keeps a limited supply of the single-dose Janssen (Johnson & Johnson), a non-mRNA vaccine. Other non-mRNA vaccines, such as Novavax, are not yet available at Public Health clinics.

Appointments can be booked for a non-mRNA COVID-19 vaccine by calling 705.674.2299 (toll-free: 1.800.708.2505) and providing a representative with your name and contact information. A representative will call you back to schedule an appointment once enough individuals have requested to receive a non-mRNA COVID-19 vaccine.

Eligibility for COVID-19 vaccines

First dose eligibility

  • Individuals five years of age and older can receive a first dose of COVID-19 vaccine.
    • Pfizer-BioNTech Comirnaty pediatric dose (10 micrograms) is approved for children 5 years of age and older. Children 5 to 11 years of age must wait at least 14 days before or after receiving another vaccine prior to receiving the COVID-19 vaccine.
    • Pfizer-BioNTech Comirnaty (30 micrograms) is approved for youth who are 12 years and older.
    • The Pfizer-BioNTech Comirnaty is preferentially recommended for individuals aged 18 to 29 years old and the only approved vaccine for youth aged 12 to 17.
    • Everyone aged 29 and over can receive either Pfizer-BioNTech Comirnaty or Moderna Spikevax. These 2 mRNA vaccines can be safely interchanged.

Second dose eligibility

  • Children aged 5 to 11 who received their first pediatric dose of Pfizer-BioNTech more than 8 weeks ago.
  • Youth aged 12 years and older who received their first dose of Pfizer-BioNTech Comirnaty vaccine more than 56 days (8 weeks) ago.
  • Anyone who received their first dose of Moderna Spikevax vaccine more than 56 days (8 weeks) ago.
  • People who received AstraZeneca Vaxzevria 56 days ago (at least 8 weeks) and who would like to get an mRNA vaccine.
  • The National Advisory Committee on Immunization (NACI) and Ontario Ministry of Health recommend an optimal interval of 8 weeks (56 days) between first and second doses of a two-dose COVID-19 vaccine series (Pfizer-BioNTech Comirnaty or Moderna Spikevax). According to NACI, there is emerging evidence that longer intervals between the first and second doses of COVID-19 vaccines result in more robust and durable immune response and higher vaccine effectiveness. Public Health will administer second doses 8 weeks (56 days) following administration of a first dose, with limited exceptions.

Third dose eligibility

The Government of Ontario recommends a third dose of a COVID-19 vaccine as part of a primary vaccine series (meaning 3 doses are needed for full immunity) for the following individuals:

Booster dose eligibility

The Government of Ontario recommends a booster dose of a COVID-19 vaccine to restore protection that may have decreased over time to a level for the following individuals:

  • Individuals 18 years of age and older who received their second dose of COVID-19 vaccine at least 3 months ago (84 days, 12 weeks).
  • Individuals 12 to 17 years of age who received their second dose of COVID-19 vaccine at least six months (168 days) or 3 months (84 days) with informed consent.
  • First Nations, Inuit, and Métis adults 18 years of age and older including non-Indigenous household members, who received their second dose of COVID-19 vaccine at least 3 months ago (84 days, 12 weeks).
  • Eligible health care workers 18 years of age and older who received their second dose of COVID-19 vaccine at least 3 months ago (84 days, 12 weeks) (see details at ca/COVID-19/vaccine-clinics).
  • Individuals who received 2 doses of the AstraZeneca/COVISHIELD COVID-19 vaccine at least 3 months ago (84 days, 12 weeks).
  • Individuals who received 1 dose of the Janssen/ Johnson & Johnson COVID-19 vaccine at least 3 months ago (84 days, 12 weeks).
  • Vulnerable older adults in congregate settings who received their second dose of COVID-19 vaccine at least 3 months ago (84 days, 12 weeks) (see details at ca/COVID-19/vaccine-clinics).
  • Moderately to severely immunocompromised individuals who are eligible for a three dose primary series may receive a booster dose (a fourth dose) 6 month (168 days, 24 weeks) after their third dose.

In addition, as of 8 a.m. on Friday, February 18, 2022, Ontario is expanding booster dose eligibility to youth aged 12 to 17.

For detailed information on eligibility for first, second, and third doses, visit

Second and third dose appointments

Anyone eligible for a second or third dose can book an appointment as soon as they are eligible. To book online, visit or call 705.674.2299 (toll-free: 1.800.708.2505), between 8 a.m. and 6 p.m., Monday to Friday. For a list of scheduled clinics, visit

Preparing for a COVID-19 vaccination appointment

All vaccination clinics have COVID-safety measures in place. You must not attend a clinic if you have any symptoms of COVID-19 or if you are in isolation due to a COVID-19 exposure.

  • Bring your health card. If you do not have a health card or your health card is expired, bring another form of government-issued photo identification such as a driver’s license, passport, Status card, or birth certificate.
  • Eat and drink something before you arrive at your appointment to prevent feeling faint or dizzy while being vaccinated.
  • Do not show up until 5 minutes before your scheduled appointment.
  • When possible, please limit the number of support people attending a vaccination clinic to one person.
  • Dress for the weather, you may have to wait in line if you plan on attending a walk-in clinic.
  • Wear a top that allows for easy access to the upper arm such as a loose-fitting top or a t-shirt.
  • Wear a medical mask that covers your nose, mouth, and chin. If you do not have a medical mask, pediatric and adult medical masks will be available at the entrance to the clinic.
  • If you have symptoms of COVID-19, do not attend the clinic.

For more information or if you have questions, please talk to trusted sources such as Public Health immunizers at COVID-19 vaccine clinics, health care providers, and pharmacists, visit or call Public Health Sudbury & Districts at 705.522.9200 (toll-free 1.866.522.9200).

Adblock test (Why?)

Source link

Continue Reading


Quebec health officials confirm 25 monkeypox cases now in province – Global News



Quebec public health officials are reporting a total of 25 confirmed cases of monkeypox in the province as of Thursday.

Dr. Luc Boileau, interim public health director in the province, described it as a “serious outbreak” of the virus. Officials are investigating several more suspected cases.

“We had about 20 to 30 suspected cases under investigation so far,” Boileau said.

The province will also begin administering the Imvamune vaccine to close contacts of confirmed or suspected cases of monkeypox as soon as Friday. A single dose will be provided within four days of exposure to the virus.

Quebec’s Health Ministry said in a statement that a second dose of the vaccine could be administered, but only if the risk of exposure is “still present 28 days later” and “only following a decision by public health authorities.”

READ MORE: Mass vaccinations for monkeypox not needed, WHO official says

Boileau said the majority of confirmed cases in the province are tied mostly to men who have had sexual relations with other men. There has been one case in a person under 18.

Last week, Quebec recorded the first cases of the virus in the country. The first suspected cases were reported on May 12 in Montreal.

Monkeypox is a rare disease that comes from the same family of viruses that causes smallpox, which the World Health Organization declared eradicated around the globe in 1980.

The virus spreads through prolonged closed contact. It can cause fever, headache, muscle aches, exhaustion, swollen lymph nodes and lesions.

— with files from Global News’ Dan Spector and the Canadian Press

© 2022 Global News, a division of Corus Entertainment Inc.

Adblock test (Why?)

Source link

Continue Reading


Quebec to start monkeypox vaccination of contacts as officials confirm 25 cases



MONTREAL — Quebec’s interim public health director says the province could start vaccinating people against monkeypox as soon as Friday.

Dr. Luc Boileau says there are now 25 confirmed cases of the disease in the province and about 30 suspected cases are under investigation.

He says the province has received supplies of smallpox vaccine from the federal government, and it will be administered to people who have been in close contact with confirmed cases of the disease.

Dr. Caroline Quach, the chair of Quebec’s immunization committee, says the vaccine has been shown to prevent monkeypox in animal studies if it is administered within four days of an exposure and can reduce severity if it is administered up to 14 days after an exposure.

She says the disease is transmitted only through prolonged close contact.

Boileau says the majority of cases are in adult men who have been in sexual contact with people who have the disease, and there has been one case in a person under 18.

This report by The Canadian Press was first published May 26, 2022.


The Canadian Press

Continue Reading


Monkeypox Warnings Ignored; Dominant COVID Strain Emerges; Better Paxlovid Access – Medpage Today



Note that some links may require registration or subscription.

Warning signs of the current monkeypox outbreak may have been ignored. (STAT)

The CDC issued a monkeypox travel alert encouraging “enhanced precautions” after cases were reported in North America, Europe, and Australia.

Roche announced it has developed three PCR test kits to detect the monkeypox virus.

The U.S. has a new dominant COVID-19 strain — BA.2.12.1 — a highly contagious sublineage of the BA.2 omicron subvariant that now accounts for 57.9% of all cases, according to CDC estimates.

Washington Gov. Jay Inslee, as well as Lt. Gov.Denny Heck, both tested positive for COVID-19, as did U.S. Rep. Liz Cheney (R-Wyo.). (Seattle Times, The Hill)

As of Thursday at 8:00 a.m. EDT, the unofficial U.S. COVID toll was 83,697,199 cases and 1,004,558 deaths, increases of 218,146 and 913, respectively, compared with this time Wednesday morning.

The Biden Administration, projecting COVID infections will continue to spread during the summer travel season announced additional steps to make nirmatrelvir/ritonavir (Paxlovid) more accessible. (ABC News)

The White House also reported the launch of the first federally-supported test-to-treat COVID site.

U.K. Prime Minister Boris Johnson and other senior leaders of the government are to blame for booze-filled parties that violated the country’s COVID-19 lockdown rules, according to an investigative report. (NPR)

A mouse study suggested that maraviroc (Selzentry), a FDA-approved drug used to treat HIV, may be able to reverse middle-aged memory loss. (Nature)

The University of California system will be paying nearly $700 million to women who said they were sexually abused by a UCLA gynecologist over the course of several decades. (AP)

The parents of a 4-year-old girl spoke out about her mysterious case of pediatric hepatitis that required a liver transplant, one of 180 similar cases under investigation in the U.S. (Today)

Teva Pharmaceuticals has issued a voluntary nationwide recall of one lot of anagrelide capsules, which are used to treat thrombocythemia secondary to myeloproliferative neoplasms, due to dissolution test failure during routine stability testing.

Servier announced the FDA approved ivosidenib (Tibsovo) in combination with azacitidine for certain patients with newly diagnosed IDH1-mutated acute myeloid leukemia.

A report from the American Medical Association shows that payers are not following the prior authorization reforms agreed to in 2018. (Fierce Healthcare)

The mass shooting in Buffalo earlier this month is a reminder that millions of Americans don’t have easy access to grocery stores. (NPR)

COVID-era misinformation is leading a wave of parents to reject ordinary childhood immunizations. (New York Times)

The FDA issued guidance spelling out rules for states that want to import certain prescription drugs from Canada.

  • Mike Bassett is a staff writer focusing on oncology and hematology. He is based in Massachusetts.

Please enable JavaScript to view the comments powered by Disqus.

Adblock test (Why?)

Source link

Continue Reading